US FDA: drug makers mostly on time with post-marketing studies
This article was originally published in SRA
Executive Summary
Most drug and biologic makers required to conduct post-marketing studies met their US commitments in fiscal year 2011 of completing studies on time or progressing on schedule, the Food and Drug Administration has reported1.